Rafael Q4 losses narrow year-over-year
Rafael Holdings reported narrowed Q4 and FY26 net losses driven by lower admin costs and a gain on settlements. While Q4 Net Loss narrowed to $9.2M, full year R&D expenses increased due to Cyclo Therapeutics consolidation.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed